Clinical Trial Update: Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and immunogenicity of the malaria vaccine candidate ChAd63 CS administered alone or with MVA CS; early immunogenicity and safety …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• ChAd63 CS
• MVA CS

Snippet

Sponsor: University of Oxford | Conditions: Malaria | Phase 1 | Status: COMPLETED